GenMark Diagnostics (Nasdaq: GNMK) reported earnings on Nov. 7. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q3), GenMark Diagnostics crushed expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly and GAAP loss per share dropped.

Margins increased across the board.

Revenue details
 GenMark Diagnostics logged revenue of $5.3 million. The three analysts polled by S&P Capital IQ wanted to see revenue of $4.3 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $1.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at -$0.20. The three earnings estimates compiled by S&P Capital IQ averaged -$0.20 per share. GAAP EPS were -$0.20 for Q3 compared to -$0.31 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 42.4%, 7,800 basis points better than the prior-year quarter. Operating margin was -118.6%, 34,530 basis points better than the prior-year quarter. Net margin was -118.9%, 36,080 basis points better than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $5.6 million. On the bottom line, the average EPS estimate is -$0.19.

Next year's average estimate for revenue is $15.6 million. The average EPS estimate is -$0.95.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 10 members out of 11 rating the stock outperform, and one members rating it underperform. Among three CAPS All-Star picks (recommendations by the highest-ranked CAPS members), two give GenMark Diagnostics a green thumbs-up, and one give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on GenMark Diagnostics is buy, with an average price target of $9.17.